Considering the clinical interest in BET domain inhibitors for treating medulloblastomas (44, 45), we also tested whether SMOi-resistant Ptch;p53 SI-CSC medulloblastomas remain sensitive to JQ1, a small-molecule inhibitor of BRD4 and other BET domain proteins. Here, TP53 is linked to medulloblastoma.